© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
September 19, 2022
Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.
September 07, 2022
The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
August 30, 2022
David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.
August 30, 2022
Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.
August 30, 2022
Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.
August 30, 2022
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.
August 30, 2022
Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.
August 30, 2022
Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.
August 30, 2022
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.
August 08, 2022
According to the company, this Phase 1 dose escalations study will evaluate the safety and tolerability of intravitreal injection of IBI324 in subjects with DME.